Learn / Epidemiology / Infectious disease epidemiology
HIV, tuberculosis and malaria: the big three in Africa
14 minute read · 6-question quiz
What you will learn
Describe the epidemiology and control principles of HIV, TB and malaria
Interpret key indicators for each disease
Explain how the three interact and why integrated programmes are needed
These three diseases dominate the infectious burden in sub-Saharan Africa and the work of many health systems, research institutes and CROs. This lesson summarises the key epidemiological ideas. Global figures change each year; use the latest WHO and UNAIDS reports for numbers you quote.
HIV
Transmission
Unprotected sex, mother-to-child (pregnancy, birth, breastfeeding), blood and needles. Per-act risk differs widely; viral load drives infectiousness.
Key concept: U=U
People on effective ART with an undetectable viral load do not transmit HIV sexually. Treatment is prevention.
Prevention package
Condoms, voluntary medical male circumcision, PrEP (oral, injectable), PMTCT, harm reduction, testing and early treatment.
Indicators
Prevalence, incidence per 100 person-years, the 95-95-95 cascade, viral suppression, vertical transmission rate, incidence in adolescent girls and young women.
In high-prevalence settings, HIV incidence is concentrated in adolescent girls and young women and their partners; key populations (sex workers, men who have sex with men, people who inject drugs) carry disproportionate risk everywhere. Population-based surveys (UPHIA, DHS) and cohorts (Rakai) give the best incidence data. Because treatment keeps people alive, prevalence falls slowly even when incidence drops.
Tuberculosis
Transmission
Airborne from people with pulmonary TB. Infection becomes active disease in about 5 to 10% over a lifetime; risk is far higher with HIV, malnutrition, diabetes and smoking.
Control
Find and treat cases quickly, contact investigation, preventive treatment for contacts and people with HIV, infection control, BCG for children.
Diagnosis
Symptom screening, rapid molecular tests (Xpert and similar), culture and drug-susceptibility testing, chest X-ray with computer-aided reading.
Indicators
Incidence per 100,000, notification rate, treatment success rate, proportion of cases tested for HIV, drug-resistant TB (RR/MDR-TB), preventive treatment coverage.
The 'missing millions' are people with TB who are never diagnosed or notified; closing this gap is the major challenge. Drug-resistant TB needs longer, costlier regimens, though shorter all-oral regimens are now available.
Malaria
Transmission
Bite of an infected female Anopheles mosquito. Intensity is measured by the entomological inoculation rate (infective bites per person per year).
Immunity
Partial immunity develops after repeated infection, so severe disease is concentrated in young children and pregnant women in high-transmission areas.
Control
Insecticide-treated nets, indoor residual spraying, prompt diagnosis and artemisinin combination therapy, seasonal malaria chemoprevention, intermittent preventive treatment in pregnancy and the RTS,S and R21 vaccines.
Indicators
Parasite prevalence in children 2 to 10 (PfPR), incidence per 1,000, slide positivity, net use, treatment-seeking, test positivity rate, deaths.
Challenges include insecticide resistance, drug resistance (partial artemisinin resistance has emerged in East Africa), Anopheles stephensi invasion of urban areas, humanitarian crises and funding gaps.
How they interact
Summary
HIV: incidence, the 95-95-95 cascade and U=U define progress; prevention is combination prevention.
TB: finding the missing cases, preventive treatment and fast diagnostics are central.
Malaria: nets, spraying, prompt treatment, chemoprevention and vaccines, against the threat of resistance.
HIV drives TB and complicates malaria in pregnancy; integrated services are more efficient.
Choose the indicator that fits each disease and cite the latest report.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.